Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma

Background The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated the gene expression and clinical significance of FGFR4 and related pathways in intrahepatic cholangiocarcinoma (iCCA). Results The median age was 56 years (range 30–78) and 34 patients (74%) were male. Six patients (13%) had hepatitis B virus infection, with or without liver cirrhosis. Overall survival was significantly associated with FGFR4 (p = 0.004), FGF19 (p = 0.047), FGF21 (p = 0.04), and KLB (p = 0.03) expression. In the multivariate analysis with potential prognostic factors, high expression of FGF19, FGF21, and FGFR4 was significantly associated with better survival. In the analysis using the TCGA iCCA dataset, mRNA overexpression of at least 1 of the FGFR4-related genes was significantly associated with better disease-free survival (p = 0.02). Materials and Methods We assessed the expression of 98 genes in formalin-fixed paraffin embedded tumor tissue specimens from 46 patients with surgically resected iCCA using a NanoString platform. This included 10 FGF pathway genes (e.g. FGFR1-4, KLB, FGF3, 4, 19, 21, and 23), 19 distal marker genes (e.g. CYP7A1 and CYP17A1), 31 genes relevant to HCC and iCCA (e.g. AFP, TS), 18 copy number variation matched genes, and 20 control genes. Log-transformation of gene expression was performed for normalization and statistical analysis. Overall survival was correlated with gene expression (< median vs. ≥ median) using a log-rank test. The prognostic impact of FGFR4-related genes was validated using the public TCGA dataset for iCCA. Conclusions Our results indicate that mRNA expression of FGFR4-related genes may be a biomarker to define the distinctive molecular phenotype of iCCA. Future preclinical and clinical validation is required to define the role of the FGFR4 pathway in iCCA.

[1]  P. Stephens,et al.  Biliary cancer: Utility of next‐generation sequencing for clinical management , 2016, Cancer.

[2]  Yoon-Koo Kang,et al.  Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers , 2016, Oncotarget.

[3]  F. Meric-Bernstam,et al.  FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. , 2016 .

[4]  David M. Jones,et al.  Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets , 2015, Journal of Clinical Pathology.

[5]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[6]  Hiromi Nakamura,et al.  Genomic spectra of biliary tract cancer , 2015, Nature Genetics.

[7]  N. Bardeesy,et al.  Biliary Tract Cancers: Finding Better Ways to Lump and Split. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Nicolas Stransky,et al.  First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. , 2015, Cancer discovery.

[9]  W. Sung,et al.  Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.

[10]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[11]  Sen Guo,et al.  Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. , 2014, Biochemical and biophysical research communications.

[12]  David M. Jones,et al.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.

[13]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[14]  M. Miyazaki,et al.  Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma , 2012, BMC Cancer.

[15]  P. Malfertheiner,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer , 2010, Expert review of gastroenterology & hepatology.

[16]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[17]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[18]  S. Kliewer,et al.  Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.

[19]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[20]  A. Ullrich,et al.  Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. , 2009, Journal of hepatology.